These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 30917396)

  • 1. [Initiation of clinical multicentre studies with local radiotracer production - Regulatory environment and radiopharmaceutical-organisational aspects].
    Zippel C; Neels OC; Hennrich U; Giesel FL; Kopka K
    Nuklearmedizin; 2019 Mar; 58(2):77-85. PubMed ID: 30917396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New Clinical Indications for (18)F/(11)C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature.
    Evangelista L; Briganti A; Fanti S; Joniau S; Reske S; Schiavina R; Stief C; Thalmann GN; Picchio M
    Eur Urol; 2016 Jul; 70(1):161-175. PubMed ID: 26850970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and pre-clinical evaluation of a new class of high-affinity
    Kelly J; Amor-Coarasa A; Nikolopoulou A; Kim D; Williams C; Ponnala S; Babich JW
    Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):647-661. PubMed ID: 27847991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrated
    Lütje S; Cohnen J; Gomez B; Grüneisen J; Sawicki L; Rübben H; Bockisch A; Umutlu L; Pöppel TD; Wetter A
    Nuklearmedizin; 2017 Jun; 56(3):73-81. PubMed ID: 28401244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gallium-68 Prostate-Specific Membrane Antigen PET Imaging.
    Hofman MS; Iravani A
    PET Clin; 2017 Apr; 12(2):219-234. PubMed ID: 28267455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a Ga-68 labeled PET tracer with short linker for prostate-specific membrane antigen (PSMA) targeting.
    Moon SH; Hong MK; Kim YJ; Lee YS; Lee DS; Chung JK; Jeong JM
    Bioorg Med Chem; 2018 May; 26(9):2501-2507. PubMed ID: 29655611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation of a [Al
    Al-Momani E; Israel I; Samnick S
    Appl Radiat Isot; 2017 Dec; 130():102-108. PubMed ID: 28950199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biodistribution and radiation dosimetry of (68)Ga-PSMA HBED CC-a PSMA specific probe for PET imaging of prostate cancer.
    Pfob CH; Ziegler S; Graner FP; Köhner M; Schachoff S; Blechert B; Wester HJ; Scheidhauer K; Schwaiger M; Maurer T; Eiber M
    Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1962-70. PubMed ID: 27207281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New aspects of molecular imaging in prostate cancer.
    Ceci F; Castellucci P; Cerci JJ; Fanti S
    Methods; 2017 Nov; 130():36-41. PubMed ID: 28711565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Translation and First In-Human Use of [
    Eppard E; de la Fuente A; Benešová M; Khawar A; Bundschuh RA; Gärtner FC; Kreppel B; Kopka K; Essler M; Rösch F
    Theranostics; 2017; 7(18):4359-4369. PubMed ID: 29158832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical Comparative Study of (68)Ga-Labeled DOTA, NOTA, and HBED-CC Chelated Radiotracers for Targeting PSMA.
    Ray Banerjee S; Chen Z; Pullambhatla M; Lisok A; Chen J; Mease RC; Pomper MG
    Bioconjug Chem; 2016 Jun; 27(6):1447-55. PubMed ID: 27076393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy.
    Morigi JJ; Stricker PD; van Leeuwen PJ; Tang R; Ho B; Nguyen Q; Hruby G; Fogarty G; Jagavkar R; Kneebone A; Hickey A; Fanti S; Tarlinton L; Emmett L
    J Nucl Med; 2015 Aug; 56(8):1185-90. PubMed ID: 26112024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of bone scintigraphy and
    Pyka T; Okamoto S; Dahlbender M; Tauber R; Retz M; Heck M; Tamaki N; Schwaiger M; Maurer T; Eiber M
    Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2114-2121. PubMed ID: 27290607
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Herlemann A; Wenter V; Kretschmer A; Thierfelder KM; Bartenstein P; Faber C; Gildehaus FJ; Stief CG; Gratzke C; Fendler WP
    Eur Urol; 2016 Oct; 70(4):553-557. PubMed ID: 26810345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer.
    Benešová M; Schäfer M; Bauder-Wüst U; Afshar-Oromieh A; Kratochwil C; Mier W; Haberkorn U; Kopka K; Eder M
    J Nucl Med; 2015 Jun; 56(6):914-20. PubMed ID: 25883127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Operation of a radiopharmacy for a clinical trial.
    Norenberg JP; Petry NA; Schwarz S
    Semin Nucl Med; 2010 Sep; 40(5):347-56. PubMed ID: 20674594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical evaluation of 86Y-labeled inhibitors of prostate-specific membrane antigen for dosimetry estimates.
    Banerjee SR; Foss CA; Pullambhatla M; Wang Y; Srinivasan S; Hobbs RF; Baidoo KE; Brechbiel MW; Nimmagadda S; Mease RC; Sgouros G; Pomper MG
    J Nucl Med; 2015 Apr; 56(4):628-34. PubMed ID: 25722448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [
    Di Iorio V; Boschi S; Sarnelli A; Cuni C; Bianchini D; Monti M; Gorgoni G; Paganelli G; Matteucci F; Masini C
    Pharmaceuticals (Basel); 2021 Jun; 14(7):. PubMed ID: 34206461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Rise of PSMA Ligands for Diagnosis and Therapy of Prostate Cancer.
    Afshar-Oromieh A; Babich JW; Kratochwil C; Giesel FL; Eisenhut M; Kopka K; Haberkorn U
    J Nucl Med; 2016 Oct; 57(Suppl 3):79S-89S. PubMed ID: 27694178
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Malaspina S; De Giorgi U; Kemppainen J; Del Sole A; Paganelli G
    Radiol Med; 2018 Dec; 123(12):952-965. PubMed ID: 30116970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.